By Fineline Cube China-based Yipinhong Pharmacy Co., Ltd (SHA: 300723) has announced that its pipeline candidate AR882, under co-development with Arthrosi Therapeutics Inc., has obtained clinical trial approval from the National Medical Products Administration (NMPA). The targeted indication is gout, a condition characterized by high levels of uric acid in the blood.
Drug Profile and Mechanism of Action
AR882 is a highly effective and selective uric acid transporter (URAT1) inhibitor capable of promoting the normalization of urine urate excretion and reducing serum uric acid (sUA) levels. Compared to other anti-gout drugs such as benzbromarone, AR882 can bind to the uric acid transporter for a longer period, prolonging inhibition. Clinical results have shown that its efficacy lasts up to 24 hours. Additionally, its ability to block the reabsorption of uric acid around the clock does not increase the kidney load, meaning no nephrotoxicity.
Global Phase IIb Study and Future Prospects
The global Phase IIb study for AR882 has completed patient enrollment in the US, New Zealand, Australia, and Taiwan, and is already producing signs of excellent efficacy and safety. This approval from the NMPA positions Yipinhong to further advance the clinical development of AR882, addressing significant unmet medical needs in the treatment of gout and improving patient outcomes.-Fineline Info & Tech